There is no experience of acute overdose with Zoledronic acid. Two patients received Zoledronic acid 32 mg over 5 minutes in clinical trials. Neither patients experienced any clinical nor laboratory toxicity. Over dosage may cause clinically significant hypocalcaemia, hypophosphatemia, and hypomagnesaemia. Clinically relevant reduction in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively.